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Isolation and characterization of a bat SARS-like
coronavirus that uses the ACE2 receptor
Xing-Yi Ge1*, Jia-Lu Li1*, Xing-LouYang1*, Aleksei A. Chmura2, Guangjian Zhu2, JonathanH. Epstein2, JonnaK.Mazet3, BenHu1,
Wei Zhang1, Cheng Peng1, Yu-Ji Zhang1, Chu-Ming Luo1, Bing Tan1, Ning Wang1, Yan Zhu1, Gary Crameri4, Shu-Yi Zhang5,
Lin-Fa Wang4,6, Peter Daszak2 & Zheng-Li Shi1
The 2002–3 pandemic caused by severe acute respiratory syndrome
coronavirus (SARS-CoV)was one of themost significant public health
events in recent history1. An ongoing outbreak ofMiddle East respira-
tory syndromecoronavirus2 suggests that thisgroupofviruses remains
a key threat and that their distribution is wider than previously recog-
nized. Although bats have been suggested to be the natural reservoirs
of both viruses3–5, attempts to isolate the progenitor virus of SARS-
CoV from bats have been unsuccessful. Diverse SARS-like corona-
viruses (SL-CoVs) have now been reported from bats in China,
Europe and Africa5–8, but none is considered a direct progenitor
of SARS-CoVbecause of their phylogenetic disparity from this virus
and the inability of their spikeproteins touse the SARS-CoVcellular
receptor molecule, the human angiotensin converting enzyme II
(ACE2)9,10.Herewe reportwhole-genome sequences of twonovel bat
coronaviruses fromChinese horseshoe bats (family: Rhinolophidae)
inYunnan,China:RsSHC014andRs3367.These viruses are farmore
closely related to SARS-CoV than any previously identified bat coro-
naviruses, particularly in the receptor binding domain of the spike
protein. Most importantly, we report the first recorded isolation of
a live SL-CoV (bat SL-CoV-WIV1) from bat faecal samples in Vero
E6 cells,which has typical coronavirusmorphology, 99.9% sequence
identity to Rs3367 and uses ACE2 fromhumans, civets andChinese
horseshoe bats for cell entry. Preliminary in vitro testing indicates
thatWIV1 also has a broad species tropism.Our results provide the
strongest evidence to date that Chinese horseshoe bats are natural
reservoirs of SARS-CoV, and that intermediate hosts may not be
necessary fordirect human infectionby somebat SL-CoVs.Theyalso
highlight the importanceof pathogen-discoveryprograms targeting
high-risk wildlife groups in emerging disease hotspots as a strategy
for pandemic preparedness.
The 2002–3 pandemic of SARS1 and the ongoing emergence of the
Middle East respiratory syndrome coronavirus (MERS-CoV)2 demon-
strate that CoVs are a significant public health threat. SARS-CoV was
shown to use the human ACE2molecule as its entry receptor, and this
is consideredahallmarkof its cross-species transmissibility11.The receptor
binding domain (RBD) located in the amino-terminal region (amino
acids 318–510) of the SARS-CoV spike (S) protein is directly involved
in binding to ACE2 (ref. 12). However, despite phylogenetic evidence
that SARS-CoV evolved from bat SL-CoVs, all previously identified
SL-CoVshavemajor sequence differences fromSARS-CoV in theRBD
of their S proteins, including one or twodeletions6,9. Replacing theRBD
of one SL-CoV S protein with SARS-CoV S conferred the ability to use
human ACE2 and replicate efficiently inmice9,13. However, to date, no
SL-CoVs have been isolated frombats, andnowild-type SL-CoVof bat
origin has been shown to use ACE2.
Weconducteda12-month longitudinal survey (April 2011–September
2012) of SL-CoVs in a colony ofRhinolophus sinicus at a single location
inKunming, YunnanProvince,China (ExtendedData Table 1).A total
of 117 anal swabs or faecal samples were collected from individual bats
using a previously published method5,14. A one-step reverse transcrip-
tion (RT)-nested PCR was conducted to amplify the RNA-dependent
RNA polymerase (RdRP)motifs A and C, which are conserved among
alphacoronaviruses and betacoronaviruses15.
Twenty-seven of the 117 samples (23%) were classed as positive by
PCR and subsequently confirmed by sequencing. The species origin of
all positive samples was confirmed to be R. sinicus by cytochrome b
sequence analysis, as described previously16. A higher prevalence was
observed in samples collected in October (30% in 2011 and 48.7% in
2012) than those inApril (7.1% in2011)orMay (7.4%in2012) (Extended
Data Table 1). Analysis of the S protein RBD sequences indicated the
presence of seven different strains of SL-CoVs (Fig. 1a and Extended
DataFigs1 and2). Inaddition toRBDsequences,which closelymatched
previously described SL-CoVs (Rs672, Rf1 andHKU3)5,8,17,18, two novel
strains (designated SL-CoV RsSHC014 and Rs3367) were discovered.
Their full-length genome sequences were determined, and both were
found to be 29,787 base pairs in size (excluding the poly(A) tail). The
overall nucleotide sequence identity of these two genomeswith human
SARS-CoV (Tor2 strain) is 95%, higher than that observed previously
for bat SL-CoVs inChina (88–92%)5,8,17,18 or Europe (76%)6 (Extended
Data Table 2 and Extended Data Figs 3 and 4). Higher sequence iden-
tities were observed at the protein level between these new SL-CoVs
and SARS-CoVs (Extended Data Tables 3 and 4). To understand the
evolutionary origin of these two novel SL-CoV strains, we conducted
recombination analysis with the Recombination Detection Program
4.0 package19 using available genome sequences of bat SL-CoV strains
(Rf1, Rp3, Rs672, Rm1, HKU3 and BM48-31) and human and civet
representative SARS-CoV strains (BJ01, SZ3, Tor2 and GZ02). Three
breakpoints were detected with strong P values (,10220) and supported
by similarity plot andbootscan analysis (ExtendedDataFig. 5a, b). Break-
points were located at nucleotides 20,827, 26,553 and 28,685 in the
Rs3367 (and RsSHC014) genome, and generated recombination frag-
ments covering nucleotides 20,827–26,533 (5,727 nucleotides) (inclu-
ding partial open reading frame (ORF) 1b, full-length S, ORF3, E and
partial M gene) and nucleotides 26,534–28,685 (2,133 nucleotides)
(including partial ORFM, full-length ORF6, ORF7, ORF8 and partial
Ngene).Phylogenetic analysisusing themajorandminorparental regions
suggested thatRs3367,orRsSHC014, is thedescendentofa recombination
of lineages that ultimately lead to SARS-CoV and SL-CoVRs672 (Fig. 1b).
The most notable sequence differences between these two new SL-
CoVs and previously identified SL-CoVs is in the RBD regions of their
Sproteins. First, theyhavehigher aminoacid sequence identity to SARS-
CoV (85% and 96% for RsSHC014 and Rs3367, respectively). Second,
there are no deletions and they have perfect sequence alignment with
the SARS-CoV RBD region (Extended Data Figs 1 and 2). Structural
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and mutagenesis studies have previously identified five key residues
(amino acids 442, 472, 479, 487 and 491) in the RBD of the SARS-CoV
S protein that have a pivotal role in receptor binding20,21. Although all
five residues in the RsSHC014 S protein were found to be different
from those of SARS-CoV, two of the five residues in the Rs3367 RBD
were conserved (Fig. 1 and Extended Data Fig. 1).
Despite the rapid accumulation of bat CoV sequences in the last
decade, there has been no report of successful virus isolation6,22,23. We
attempted isolation from SL-CoV PCR-positive samples. Using an
optimized protocol and Vero E6 cells, we obtained one isolate which
caused cytopathic effect during the secondblindpassage. Purified virions
displayed typical coronavirus morphology under electron microscopy
(Fig. 2). Sequence analysis using a sequence-independent amplifica-
tion method14 to avoid PCR-introduced contamination indicated that
the isolatewas almost identical to Rs3367,with 99.9%nucleotide genome
sequence identity and 100% amino acid sequence identity for the S1
region. The new isolate was named SL-CoV-WIV1.
TodeterminewhetherWIV1canuseACE2as a cellular entry receptor,
we conducted virus infectivity studies using HeLa cells expressing or
not expressing ACE2 from humans, civets or Chinese horseshoe bats.
We found thatWIV1 is able touseACE2of different origins as an entry
receptor and replicated efficiently in theACE2-expressing cells (Fig. 3).
This is, to our knowledge, the first identification of a wild-type bat SL-
CoV capable of using ACE2 as an entry receptor.
Toassess its cross-species transmissionpotential,we conducted infec-
tivity assays in cell lines from a range of species. Our results (Fig. 4 and
Extended Data Table 5) indicate that bat SL-CoV-WIV1 can grow in
human alveolar basal epithelial (A549), pig kidney 15 (PK-15) and
Rhinolophus sinicus kidney (RSKT) cell lines, but not in human cervix
(HeLa), Syrian golden hamster kidney (BHK21),Myotis davidii kidney
(BK),Myotis chinensis kidney (MCKT), Rousettus leschenaulti kidney
(RLK) or Pteropus alecto kidney (PaKi) cell lines. Real-time RT–PCR
indicated that WIV1 replicated much less efficiently in A549, PK-15
and RSKT cells than in Vero E6 cells (Fig. 4).
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Figure 1 | Phylogenetic tree based on amino acid sequences of the S RBD
region and the two parental regions of bat SL-CoV Rs3367 or RsSHC014.
a, SARS-CoV S protein amino acid residues 310–520 were aligned with
homologous regions of bat SL-CoVs using the ClustalW software. A maximum-
likelihood phylogenetic tree was constructed using a Poisson model with
bootstrap values determined by 1,000 replicates in theMEGA5 software package.
The RBD sequences identified in this study are in bold and named by the sample
numbers. The key amino acid residues involved in interacting with the human
ACE2molecule are indicated on the right of the tree. SARS-CoVGZ02, BJ01 and
Tor2 were isolated frompatients in the early, middle and late phase, respectively,
of the SARS outbreak in 2003. SARS-CoV SZ3 was identified from Paguma
larvata in 2003 collected inGuangdong,China. SL-CoVRp3,Rs672 andHKU3-1
were identified from R. sinicus collected in China (respectively: Guangxi, 2004;
Guizhou, 2006; Hong Kong, 2005). Rf1 and Rm1 were identified from
R. ferrumequinum and R. macrotis, respectively, collected in Hubei, China, in
2004. Bat SARS-related CoV BM48-31 was identified from R. blasii collected in
Bulgaria in 2008. Bat CoV HKU9-1 was identified from Rousettus leschenaultii
collected in Guangdong, China in 2005/2006 and used as an outgroup. All
sequences in bold and italics were identified in the current study. Filled triangles,
circles and diamonds indicate samples with co-infection by two different
SL-CoVs. ‘–’ indicates the amino acid deletion. b, Phylogenetic origins of the two
parental regions of Rs3367 or RsSHC014. Maximum likelihood phylogenetic
trees were constructed from alignments of two fragments covering nucleotides
20,827–26,533 (5,727 nucleotides) and 26,534 –28,685 (2,133 nucleotides) of the
Rs3367 genome, respectively. For display purposes, the trees were midpoint
rooted. The taxa were annotated according to strain names: SARS-CoV, SARS
coronavirus; SARS-likeCoV,bat SARS-like coronavirus.The twonovel SL-CoVs,
Rs3367 and RsSHC014, are in bold and italics.
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To assess the cross-neutralization activity of human SARS-CoV sera
against WIV1, we conducted serum-neutralization assays using nine
convalescent sera from SARS patients collected in 2003. The results
showed that sevenof thesewere able to completely neutralize 100 tissue
culture infectious dose 50 (TCID50) WIV1 at dilutions of 1:10 to 1:40,
further confirming the close relationshipbetweenWIV1andSARS-CoV.
Our findings have important implications for public health. First,
they provide the clearest evidence yet that SARS-CoVoriginated inbats.
Our previouswork provided phylogenetic evidence of this5, but the lack
of an isolate or evidence that bat SL-CoVs can naturally infect human
cells, until now, had cast doubt on this hypothesis. Second, the lack of
capacity of SL-CoVs to use of ACE2 receptors has previously been
consideredas thekeybarrier for theirdirect spillover intohumans, suppor-
ting the suggestion that civets were intermediate hosts for SARS-CoV
adaptation tohuman transmissionduring theSARSoutbreak24.However,
the ability of SL-CoV-WIV1 to use human ACE2 argues against the
necessity of this step for SL-CoV-WIV1 and suggests that direct bat-
to-human infection is a plausible scenario for some bat SL-CoVs. This
has implications for public health controlmeasures in the face of poten-
tial spillover of a diverse andgrowingpool of recently discovered SARS-
like CoVs with a wide geographic distribution.
Our findings suggest that the diversity of bat CoVs is substantially
higher than thatpreviously reported. In this studywewereable todemon-
strate the circulationof at least sevendifferent strains of SL-CoVswithin a
single colony of R. sinicus during a 12-month period. The high genetic
diversity of SL-CoVs within this colony was mirrored by high pheno-
typic diversity in the differential use of ACE2 by different strains. It
would therefore not be surprising if further surveillance reveals a broad
diversity of bat SL-CoVs that are able to use ACE2, some of whichmay
have even closer homology to SARS-CoV than SL-CoV-WIV1. Our
results—in addition to the recent demonstration of MERS-CoV in a
Saudi Arabian bat25, and of bat CoVs closely related to MERS-CoV in
China, Africa, Europe andNorthAmerica3,26,27—suggest that bat coro-
naviruses remain a substantial global threat to public health.
Finally, this study demonstrates the public health importance of path-
ogendiscoveryprograms targetingwildlife that aimto identify the ‘known
unknowns’—previously unknown viral strains closely related to known
pathogens. These programs, focused on specific high-risk wildlife groups
and hotspots of disease emergence, may be a critical part of future global
strategies to predict, prepare for, and prevent pandemic emergence28.
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Figure 3 | Analysis of receptor usage of SL-CoV-WIV1 determined by
immunofluorescence assay and real-time PCR. Determination of virus
infectivity in HeLa cells with and without the expression of ACE2. b, bat;
c, civet; h, human. ACE2 expression was detected with goat anti-humanACE2
antibody followed by fluorescein isothiocyanate (FITC)-conjugated donkey
anti-goat IgG. Virus replication was detected with rabbit antibody against the
SL-CoV Rp3 nucleocapsid protein followed by cyanine 3 (Cy3)-conjugated
mouse anti-rabbit IgG. Nuclei were stained with DAPI (49,6-diamidino-2-
phenylindole). The columns (from left to right) show staining of nuclei (blue),
ACE2 expression (green), virus replication (red), merged triple-stained
images and real-time PCR results, respectively. (n5 3); error bars represent
standard deviation.
200 nm
Figure 2 | Electron micrograph of purified virions. Virions from a 10-ml
culture were collected, fixed and concentrated/purified by sucrose gradient
centrifugation. The pelleted viral particles were suspended in 100ml PBS,
stained with 2% phosphotungstic acid (pH 7.0) and examined directly using a
Tecnai transmission electron microscope (FEI) at 200 kV.
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METHODS SUMMARY
Throat and faecal swabs or fresh faecal samples were collected in viral transport
medium as described previously14. All PCRwas conducted with theOne-Step RT–
PCR kit (Invitrogen). Primers targeting the highly conserved regions of the RdRP
gene were used for detection of all alphacoronaviruses and betacoronaviruses as
described previously15. Degenerate primers were designed on the basis of all avail-
able genomic sequences of SARS-CoVs and SL-CoVs andused for amplification of
theRBD sequences of S genes or full-length genomic sequences. Degenerate primers
were used for amplification of the bat ACE2 gene as described previously29. PCR
products were gel purified and cloned into pGEM-T Easy Vector (Promega). At
least four independent cloneswere sequenced toobtain a consensus sequence. PCR-
positive faecal samples (in 200ml buffer)were gradient centrifuged at 3,000–12,000g
and supernatant diluted at 1:10 inDMEMbefore being added toVeroE6 cells.After
incubation at 37 uC for 1 h, inocula were removed and replaced with fresh DMEM
with 2%FCS. Cells were incubated at 37 uC and checked daily for cytopathic effect.
Cell lines from different origins were grown on coverslips in 24-well plates and
inoculated with the novel SL-CoV at a multiplicity of infection of 10. Virus repli-
cation was detected at 24 h after infection using rabbit antibodies against the SL-
CoV Rp3 nucleocapsid protein followed by Cy3-conjugated goat anti-rabbit IgG.
Online Content Any additional Methods, ExtendedData display items and Source
Data are available in the online version of the paper; references unique to these
sections appear only in the online paper.
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Figure 4 | Analysis of host range of SL-CoV-WIV1 determined by
immunofluorescence assay and real-time PCR. Virus infection in A549,
RSKT, Vero E6 and PK-15 cells. Virus replication was detected as described for
Fig. 3. The columns (from left to right) show staining of nuclei (blue), virus
replication (red), merged double-stained images and real-time PCR results,
respectively. n5 3; error bars represent s.d.
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METHODS
Sampling. Bats were trapped in their natural habitat as described previously5.
Throat and faecal swab samples were collected in viral transport medium (VTM)
composed of Hank’s balanced salt solution, pH7.4, containing BSA (1%), ampho-
tericin (15mgml21), penicillin G (100Uml21) and streptomycin (50mgml21). To
collect fresh faecal samples, clean plastic sheets measuring 2.0 by 2.0mwere placed
under knownbat roosting sites at about 18:00 h each evening. Relatively fresh faecal
sampleswere collected from sheets at approximately 05:30–06:00 the nextmorning
and placed in VTM. Samples were transported to the laboratory and stored at
280 uC until use. All animals trapped for this study were released back to their
habitat after sample collection. All sampling processes were performed by veter-
inarians with approval fromAnimal Ethics Committee of theWuhan Institute of
Virology (WIVH05210201) and EcoHealth Alliance under an inter-institutional
agreement with University of California, Davis (UC Davis protocol no. 16048).
RNA extraction, PCR and sequencing. RNA was extracted from 140ml of swab
or faecal sampleswith aViral RNAMiniKit (Qiagen) following themanufacturer’s
instructions. RNA was eluted in 60ml RNAse-free buffer (buffer AVE, Qiagen),
then aliquoted and stored at280 uC. One-step RT–PCR (Invitrogen) was used to
detect coronavirus sequences as described previously15. First round PCR was con-
ducted in a 25-ml reaction mix containing 12.5ml PCR 23 reaction mix buffer,
10 pmol of each primer, 2.5mM MgSO4, 20 U RNase inhibitor, 1ml SuperScript
III/ PlatinumTaqEnzymeMix and 5ml RNA.Amplification of the RdRP-gene frag-
ment was performed as follows: 50 uC for 30min, 94 uC for 2min, followed by 40
cycles consisting of 94 uC for 15 s, 62 uC for 15 s, 68 uC for 40 s, and a final exten-
sion of 68 uC for 5min. Second round PCRwas conducted in a 25-ml reactionmix
containing 2.5ml PCR reaction buffer, 5 pmol of each primer, 50mM MgCl2,
0.5mM dNTP, 0.1ml Platinum Taq Enzyme (Invitrogen) and 1 ml first round
PCR product. The amplification of RdRP-gene fragment was performed as fol-
lows: 94 uC for 5min followed by 35 cycles consisting of 94 uC for 30 s, 52 uC for
30 s, 72 uC for 40 s, and a final extension of 72 uC for 5min.
To amplify the RBD region, one-step RT–PCR was performed with primers
designed based on available SARS-CoV or bat SL-CoVs (first round PCR primers;
F, forward; R, reverse: CoVS931F-59-VWGADGTTGTKAGRTTYCCT-39 and
CoVS1909R-59-TAARACAVCCWGCYTGWGT-39; second PCR primers: CoVS
951F-59-TGTKAGRTTYCCTAAYATTAC-39 and CoVS1805R-59-ACATCYTG
ATANARAACAGC-39). First-round PCR was conducted in a 25-ml reaction mix
as described above except primers specific for the S gene were used. The ampli-
fication of theRBDregionof the S genewasperformed as follows: 50 uC for 30min,
94 uC for 2min, followed by 35 cycles consisting of 94 uC for 15 s, 43 uC for 15 s,
68 uC for 90 s, and a final extension of 68 uC for 5min. Second-round PCR was
conducted in a 25-ml reactionmix containing 2.5ml PCR reaction buffer, 5 pmol of
eachprimer, 50mMMgCl2, 0.5mMdNTP, 0.1ml PlatinumTaqEnzyme (Invitrogen)
and 1ml first round PCR product. Amplification was performed as follows: 94 uC
for 5min followed by 40 cycles consisting of 94 uC for 30 s, 41 uC for 30 s, 72 uC for
60 s, and a final extension of 72 uC for 5min.
PCRproductswere gel purified and cloned intopGEM-TEasyVector (Promega).
At least four independent clones were sequenced to obtain a consensus sequence
for each of the amplified regions.
Sequencing full-length genomes.Degenerate coronavirus primers were designed
based on all available SARS-CoVand bat SL-CoV sequences inGenBank and specific
primerswere designed fromgenome sequences generated fromprevious rounds of
sequencing in this study (primer sequences will be provided upon request). All
PCRs were conducted using the One-Step RT–PCR kit (Invitrogen). The 59 and 39
genomic ends were determined using the 59 or 39 RACE kit (Roche), respectively.
PCR products were gel purified and sequenced directly or following cloning into
pGEM-TEasyVector (Promega).At least four independent cloneswere sequenced
to obtain a consensus sequence for each of the amplified regions and each region
was sequenced at least twice.
Sequence analysis and databank accessionnumbers.Routine sequencemanage-
ment and analysis was carried out using DNAStar or Geneious. Sequence align-
ment and editing was conducted using ClustalW, BioEdit or GeneDoc.Maximum
Likelihood phylogenetic trees based on the protein sequences were constructed
using a Poissonmodel with bootstrap values determined by 1,000 replicates in the
MEGA5 software package.
Sequences obtained in this study have been deposited in GenBank as follows
(accession numbers given in parenthesis): full-length genome sequence of SL-CoV
RsSHC014 and Rs3367 (KC881005, KC881006); full-length sequence of WIV1 S
(KC881007); RBD (KC880984-KC881003); ACE2 (KC8810040). SARS-CoV
sequences used in this study: human SARS-CoV strains Tor2 (AY274119), BJ01
(AY278488), GZ02 (AY390556) and civet SARS-CoV strain SZ3 (AY304486). Bat
coronavirus sequences used in this study: Rs672 (FJ588686), Rp3 (DQ071615), Rf1
(DQ412042), Rm1 (DQ412043), HKU3-1 (DQ022305), BM48-31 (NC_014470),
HKU9-1(NC_009021),HKU4(NC_009019),HKU5(NC_009020),HKU8(DQ249228),
HKU2(EF203067), BtCoV512 (NC_009657), 1A (NC_010437).Other coronavirus
sequences used in this study:HCoV-229E (AF304460),HCoV-OC43 (AY391777),
HCoV-NL63(AY567487),HKU1(NC_006577),EMC(JX869059),FIPV(NC_002306),
PRCV (DQ811787), BWCoV (NC_010646), MHV (AY700211), IBV (AY851295).
Amplification, cloning and expression of the bat ACE2 gene. Construction of
expression clones for human and civet ACE2 in pcDNA3.1 has been described
previously29. Bat ACE2 was amplified from a R. sinicus (sample no. 3357). In brief,
total RNAwas extracted frombat rectal tissue using the RNeasyMiniKit (Qiagen).
First-strand complementaryDNAwas synthesized from total RNAby reverse trans-
cription with random hexamers. Full-length bat ACE2 fragments were amplified
using forward primer bAF2 and reverse primer bAR2 (ref. 29). TheACE2 genewas
cloned into pCDNA3.1 with KpnI and XhoI, and verified by sequencing. Purified
ACE2 plasmids were transfected to HeLa cells. After 24 h, lysates of HeLa cells
expressing human, civet, or bat ACE2 were confirmed by western blot or immu-
nofluorescence assay.
Western blot analysis. Lysates of cells or filtered supernatants containing pseu-
doviruses were separated by SDS–PAGE, followed by transfer to a nitrocellulose
membrane (Millipore). For detection of S protein, the membrane was incubated
with rabbit anti-Rp3 S fragment (amino acids 561–666) polyantibodies (1:200),
and the bound antibodies were detected by alkaline phosphatase (AP)-conjugated
goat anti-rabbit IgG (1:1,000). For detection of HIV-1 p24 in supernatants, mono-
clonal antibody against HIV p24 (p24MAb)was used as the primary antibody at a
dilution of 1:1,000, followed by incubationwithAP-conjugated goat anti-mouse IgG
at the same dilution. To detect the expression of ACE2 in HeLa cells, goat antibody
against thehumanACE2ectodomain (1:500)wasused as the first antibody, followed
by incubationwithhorseradishperoxidase-conjugateddonkeyanti-goat IgG(1:1,000).
Virus isolation.Vero E6 cell monolayers weremaintained inDMEM supplemen-
ted with 10% FCS. PCR-positive samples (in 200ml buffer) were gradient centri-
fuged at 3,000–12,000g, and supernatant were diluted 1:10 in DMEMbefore being
added toVero E6 cells. After incubation at 37 uC for 1 h, inoculawere removed and
replaced with fresh DMEMwith 2% FCS. Cells were incubated at 37 uC for 3 days
and checked daily for cytopathic effect. Double-dose triple antibiotics penicillin/
streptomycin/amphotericin (Gibco)were included in all tissue culturemedia (peni-
cillin 200 IUml21, streptomycin 0.2mgml21, amphotericin 0.5mgml21). Three
blind passageswere carried out for each sample.After eachpassage, both the culture
supernatant and cell pellet were examined for presence of virus by RT–PCR using
primers targeting the RdRP or S gene. Virions in supernatant (10ml)were collected
and fixed using 0.1% formaldehyde for 4 h, then concentrated by ultracentrifuga-
tion through a 20% sucrose cushion (5ml) at 80,000g for 90minusing a Ty90 rotor
(Beckman). The pelleted viral particles were suspended in 100ml PBS, stained with
2% phosphotungstic acid (pH 7.0) and examined using a Tecnai transmission
electron microscope (FEI) at 200 kV.
Virus infectivity detected by immunofluorescence assay.Cell lines used for this
study and their culture conditions are summarized inExtendedDataTable 5.Virus
titre was determined in Vero E6 cells by cytopathic effect (CPE) counts. Cell lines
fromdifferentorigins andHeLacells expressingACE2 fromhuman, civet orChinese
horseshoe batwere grownon coverslips in 24-well plates (Corning) incubatedwith
bat SL-CoV-WIV1 at a multiplicity of infection5 10 for 1 h. The inoculum was
removed and washed twice with PBS and supplemented with medium. HeLa cells
without ACE2 expression and Vero E6 cells were used as negative and positive
controls, respectively. At 24 h after infection, cells were washedwith PBS and fixed
with 4% formaldehyde in PBS (pH7.4) for 20min at 4 uC. ACE2 expression was
detected using goat anti-human ACE2 immunoglobulin (R&D Systems) followed
by FITC-labelled donkey anti-goat immunoglobulin (PTGLab). Virus replication
was detected using rabbit antibody against the SL-CoV Rp3 nucleocapsid protein
followedbyCy3-conjugatedmouse anti-rabbit IgG.Nucleiwere stainedwithDAPI.
Staining patterns were examined using a FV1200 confocal microscope (Olympus).
Virus infectivity detected by real-time RT–PCR. Vero E6, A549, PK15, RSKT
andHeLa cells with orwithout expression ofACE2 of different origins were inocu-
lated with 0.1 TCID50 WIV-1 and incubated for 1 h at 37 uC. After removing the
inoculum, the cells were cultured with medium containing 1% FBS. Supernatants
were collected at 0, 12, 24 and 48h. RNA from 140ml of each supernatant was
extracted with theViral RNAMini Kit (Qiagen) followingmanufacturer’s instruc-
tions and eluted in 60ml buffer AVE (Qiagen). RNA was quantified on the ABI
StepOne system, with the TaqMan AgPath-ID One-Step RT–PCR Kit (Applied
Biosystems) in a 25ml reaction mix containing 4ml RNA, 13RT–PCR enzyme
mix, 13RT–PCR buffer, 40 pmol forward primer (59-GTGGTGGTGACGGCA
AAATG-39), 40 pmol reverse primer (59-AAGTGAAGCTTCTGGGCCAG-39)
and 12pmol probe (59-FAM-AAAGAGCTCAGCCCCAGATG-BHQ1-39). Ampli-
ficationparameterswere10minat 50 uC, 10minat 95 uCand50cyclesof 15 s at 95 uC
and 20 s at 60 uC. RNAdilutions from purifiedWIV-1 stock were used as a standard.
Serumneutralization test. SARS patient sera were inactivated at 56 uC for 30min
and then used for virus neutralization testing. Sera were diluted starting with 1:10
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and then serially twofold diluted in 96-well cell plates to 1:40. Each 100ml serum
dilution wasmixed with 100ml viral supernatant containing 100TCID50 ofWIV1
and incubated at 37 uC for 1 h. Themixture was added in triplicate wells of 96-well
cell plates with plated monolayers of Vero E6 cells and further incubated at 37 uC
for 2 days. Serum from a healthy blood donor was used as a negative control in
each experiment. CPE was observed using an inverted microscope 2 days after
inoculation. The neutralizing antibody titre was read as the highest dilution of
serumwhich completely suppressed CPE in infected wells. The neutralization test
was repeated twice.
Recombination analysis. Full-length genomic sequences of SL-CoV Rs3367 or
RsSHC014were aligned with those of selected SARS-CoVs and bat SL-CoVs using
Clustal X. The aligned sequences were preliminarily scanned for recombination
events using Recombination Detection Program (RDP) 4.0 (ref. 19). The potential
recombination events suggested by RDP owing to their strong P values (,10–20)
were investigated further by similarity plot and bootscan analyses implemented in
Simplot 3.5.1. Phylogenetic origin of the major and minor parental regions of
Rs3367 or RsSHC014 were constructed from the concatenated sequences of the
essentialORFs of themajor andminor parental regions of selected SARS-CoV and
SL-CoVs. Two genome regions between three estimated breakpoints (20,827–
26,553 and 26,554–28,685) were aligned independently using ClustalX and gene-
rated two alignments of 5,727 base pairs and 2,133 base pairs. The two alignments
were used to construct maximum likelihood trees to better infer the fragment
parents. All nucleotide numberings in this study are based on Rs3367 genome
position.
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Extended Data Figure 1 | Sequence alignment of CoV S protein RBD.
SARS-CoV S protein (amino acids 310–520) is aligned with homologous
regions of bat SL-CoVs using ClustalW. The newly discovered bat SL-CoVs are
indicated with a bold vertical line on the left. The key amino acid residues
involved in the interaction with human ACE2 are numbered on the top of the
aligned sequences.
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Extended Data Figure 2 | Alignment of CoV S protein S1 sequences.
Alignment of S1 sequences (amino acids 1–660) of the two novel bat SL-CoV S
proteins with those of previously reported bat SL-CoVs and human and
civet SARS-CoVs. The newly discovered bat SL-CoVs are boxed in red.
SARS-CoV GZ02, BJ01 and Tor2 were isolated from patients in the early,
middle and late phase, respectively, of the SARS outbreak in 2003. SARS-CoV
SZ3 was identified from P. larvata in 2003 collected in Guangdong, China.
SL-CoV Rp3, Rs 672 and HKU3-1 were identified from R. sinicus collected in
Guangxi, Guizhou and Hong Kong, China, respectively. Rf1 and Rm1 were
identified from R. ferrumequinum and R. macrotis, respectively, collected in
Hubei Province, China. Bat SARS-related CoV BM48-31 was identified from
R. blasii collected in Bulgaria.
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Extended Data Figure 3 | Complete RdRP sequence phylogeny.
Phylogenetic tree of bat SL-CoVs and SARS-CoVs on the basis of complete
RdRP sequences (2,796 nucleotides). Bat SL-CoVs RsSHC014 and Rs3367 are
highlighted by filled circles. Three established coronaivirus genera,
Alphacoronavirus, Betacoronavirus andGammacoronavirus aremarked as a, b
and c, respectively. Four CoV groups in the genus Betacoronavirus are
indicated as A, B, C and D, respectively. MHV, murine hepatitis virus;
PHEV, porcine haemagglutinating encephalomyelitis virus; PRCV, porcine
respiratory coronavirus; FIPV, feline infectious peritonitis virus; IBV,
infectious bronchitis coronavirus; BW, beluga whale coronavirus.
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Extended Data Figure 4 | Sequence phylogeny of the complete S protein of
SL-CoVs and SARS-CoV. Phylogenetic tree of bat SL-CoVs and SARS-CoVs
on the basis of complete S protein sequences (1,256 amino acids).
Bat SL-CoVs RsSHC014 and Rs3367 are highlighted by filled circles. Bat CoV
HKU9 was used as an outgroup.
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Extended Data Figure 5 | Detection of potential recombination events.
a, b, Similarity plot (a) and bootscan analysis (b) detected three recombination
breakpoints in the bat SL-CoV Rs3367 or SHC014 genome. The three
breakpoints were located at the ORF1b (nt 20,827),M (nucleotides 26,553) and
N (nucleotides 28,685) genes, respectively. Both analyses were performed with
an F84 distance model, a window size of 1,500 base pairs and a step size of
300 base pairs.
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Extended Data Table 1 | Summary of sampling detail and CoV prevalence
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Extended Data Table 2 | Genomic sequence identities of bat SL-CoVs with SARS-CoVs
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Extended Data Table 3 | Genomic annotation and comparison of bat SL-CoV Rs3367 with human/civet SARS-CoVs and other bat SL-CoVs
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ExtendedData Table 4 | Genomic annotation and comparison of bat SL-CoVRsSHC014with human/civet SARS-CoVs and other bat SL-CoVs
LETTER RESEARCH
Macmillan Publishers Limited. All rights reserved©2013
Extended Data Table 5 | Cell lines used for virus isolation and susceptibility tests
* Infectivity was determined by the presence of viral antigen detected by immunofluorescence assay.
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